# Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

> **NCT00869323** · PHASE2 · TERMINATED · sponsor: **Masonic Cancer Center, University of Minnesota** · enrollment: 3 (actual)

## Conditions studied

- Lymphoproliferative Disorder

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00869323
- **Lead sponsor:** Masonic Cancer Center, University of Minnesota
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-03
- **Primary completion:** 2013-03
- **Final completion:** 2016-12
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Funding unavailable
- **Last updated:** 2017-12-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00869323

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00869323, "Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00869323. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*